Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(18 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama Mayo Clinic Arizona, Phoenix, Arizona Stanford University, Palo Alto, California Mayo Clinic Florida, Jacksonville, Florida Kansas University Medical Center, Kansas City, Kansas Johns Hopkins School of Medicine, Baltimore, Maryland Midatlantic Epilepsy and Sleep Center, Bethesda, Maryland Massachusetts General Hospital, Boston, Massachusetts Corewell Health, Grand Rapids, Michigan Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire Northeast Regional Epilepsy Group, Hackensack, New Jersey Robert Wood Johnson Hospital, New Brunswick, New Jersey Cleveland Clinic, Cleveland, Ohio Ohio State University, Columbus, Ohio Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania Allegheny Health Network, Pittsburgh, Pennsylvania Baylor Scott & White Medical Center, Austin, Texas Medical College of Wisconsin, Milwaukee, Wisconsin